Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles

Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles AbstractConsiderable development in the application of injectable drug delivery systems for cancer therapy has occurred in the last few decades. These improvements include liposomes, lipid nanoparticles (LNPs), and other nanoparticles with or without macromolecular conjugates. For example, liposomal doxorubicin modified by poly(ethylene glycol) (Doxil) was the first liposome with anti-cancer effects which was approved by the US Food and Drug Administration, whereas Abraxane (modified albumin nanoparticles loaded by paclitaxel) was recently confirmed for the treatment of breast cancer. Recently, drug delivery systems by LNPs are an emerging technology with numerous advantages over conventional liposomes and chemotherapy using free drug treatment of cancer. These properties are biocompatibility, controlled and sustained release of anti-tumor drugs, and lower toxicity. Valuable experiments on these drug delivery systems offer better treatment of multidrug-resistant cancers and lower cardiotoxicity. LNPs have been presented with high functionality in chemotherapeutic targeting of breast and prostate cancer. The basis for this targeting behavior has been shown to be both passive and active targeting. The main objective of this review was an overview of the current position of the liposome-based drug delivery systems in targeted anticancer chemotherapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drug Metabolism and Drug Interactions de Gruyter

Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles

Download PDF
8 pages

Loading next page...
 
/lp/de-gruyter/passive-and-active-targeting-in-cancer-therapy-by-liposomes-and-lipid-r9YGQ5k0Zg

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
de Gruyter
Copyright
©2019 Walter de Gruyter GmbH, Berlin/Boston
ISSN
2191-0162
eISSN
2191-0162
DOI
10.1515/dmpt-2018-0032
Publisher site
See Article on Publisher Site

Abstract

AbstractConsiderable development in the application of injectable drug delivery systems for cancer therapy has occurred in the last few decades. These improvements include liposomes, lipid nanoparticles (LNPs), and other nanoparticles with or without macromolecular conjugates. For example, liposomal doxorubicin modified by poly(ethylene glycol) (Doxil) was the first liposome with anti-cancer effects which was approved by the US Food and Drug Administration, whereas Abraxane (modified albumin nanoparticles loaded by paclitaxel) was recently confirmed for the treatment of breast cancer. Recently, drug delivery systems by LNPs are an emerging technology with numerous advantages over conventional liposomes and chemotherapy using free drug treatment of cancer. These properties are biocompatibility, controlled and sustained release of anti-tumor drugs, and lower toxicity. Valuable experiments on these drug delivery systems offer better treatment of multidrug-resistant cancers and lower cardiotoxicity. LNPs have been presented with high functionality in chemotherapeutic targeting of breast and prostate cancer. The basis for this targeting behavior has been shown to be both passive and active targeting. The main objective of this review was an overview of the current position of the liposome-based drug delivery systems in targeted anticancer chemotherapy.

Journal

Drug Metabolism and Drug Interactions – de Gruyter

Published: Mar 26, 2019

References

  • Therapeutic vaccines for cancer: an overview of clinical trials
  • Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study
  • Liposome formulations of hydrophobic drugs
  • Preparation, characterization and anti-proliferative effects of sclareol-loaded solid lipid nanoparticles on A549 human lung epithelial cancer cells
  • [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story]
  • Adoptive cell transfer as personalized immunotherapy for human cancer
  • Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E
  • Strategies to increase drug penetration in solid tumors
  • Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin’s lymphoma in mice
  • Direct transbronchial administration of liposomal amphotericin B into a pulmonary aspergilloma
  • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
  • Liposome: classification, preparation, and applications
  • Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells
  • Cancer immunotherapy comes of age
  • Nanomedicines: addressing the scientific and regulatory gap
  • Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies
  • Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation
  • Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin’s lymphoma in mice
  • Application of liposomes in medicine and drug delivery
  • Metastasis prevention by targeting the dormant niche
  • Nanoparticles in the clinic
  • Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer
  • Exceptional response to nanoparticle albumin-bound paclitaxel and gemcitabine in a patient with a refractory adenocarcinoma of the ampulla of Vater
  • Nanoparticles in the clinic
  • Novel methods for liposome preparation
  • Direct transbronchial administration of liposomal amphotericin B into a pulmonary aspergilloma
  • Effects of drug hydrophobicity on liposomal stability
  • Novel methods for liposome preparation
  • Oncolytic virotherapy
  • Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release
  • Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression
  • Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer
  • Effect of cholesterol on distribution of stable, hydrophobic perchlorotriphenylmethyl triethylester radical incorporated in lecithin liposomal membranes
  • Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy
  • Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  • Modulating effect of lipid bilayer-carotenoid interactions on the property of liposome encapsulation
  • Modulating effect of lipid bilayer-carotenoid interactions on the property of liposome encapsulation
  • Exceptional response to nanoparticle albumin-bound paclitaxel and gemcitabine in a patient with a refractory adenocarcinoma of the ampulla of Vater
  • Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy
  • Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases
  • The pharmacokinetics of liposomes in tumor targeting
  • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
  • Herbal medicines for the treatment of cancer chemotherapy-induced side effects
  • Relevancy of drug loading to liposomal formulation therapeutic efficacy
  • Relaxivities of paramagnetic liposomes: on the importance of the chain type and the length of the amphiphilic complex
  • Advancing cancer therapy with present and emerging immuno-oncology approaches